SCHEMBL6432166

SCHEMBL6432166

N/N=C(\c1ccc(O)cc1)c1nc2nonc2nc1Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
HTT P42858 2/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 4/20 0.38
CCR2 P41597 1/20 0.38
CCR5 P51681 1/20 0.38
POLB P06746 1/20 0.36
AURKA O14965 1/20 0.35
BRAF P15056 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
KDR P35968 2/20 0.34
ALOX5 P09917 1/20 0.33
VCP P55072 1/20 0.33
EPHA2 P29317 1/20 0.33
POLA1 P09884 1/20 0.33
MAOB P27338 1/20 0.32
STK17B O94768 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6432179 1.00 MAPT (0.38) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6418336 0.91 MAPT (0.39) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6418314 0.91 MAPT (0.39) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6412964 0.89 MAPT (0.40) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6412976 0.89 MAPT (0.40) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6416496 0.87 MAPT (0.36) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6416484 0.87 MAPT (0.36) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6418260 0.86 TP53 (0.42) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6436004 0.86 TP53 (0.42) MAPTSMN1; SMN2MEN1KMT2AHTT
SCHEMBL6435799 0.84 SMN1; SMN2 (0.43) MAPTSMN1; SMN2MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885SMN1; SMN2 4369/4885MEN1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.